Live Earnings Conference Call: Amgen will host a live Q1 2025 earnings call on May 1, 2025 at 4:30PM ET. Follow this link to get details and listen to Amgen's Q1 2025 earnings call when it goes live. Get details. Amgen (AMGN) Competitors $290.92 +2.36 (+0.82%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMGN vs. GILD, VRTX, REGN, ALNY, BIIB, UTHR, BMRN, INCY, EXEL, and NBIXShould you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exelixis (EXEL), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry. Amgen vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Exelixis Neurocrine Biosciences Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk. Does the MarketBeat Community prefer AMGN or GILD? Gilead Sciences received 931 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.86% of users gave Gilead Sciences an outperform vote while only 71.81% of users gave Amgen an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes155471.81% Underperform Votes61028.19% Gilead SciencesOutperform Votes248576.86% Underperform Votes74823.14% Is AMGN or GILD a better dividend stock? Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 3.0%. Amgen pays out 126.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Which has preferable valuation & earnings, AMGN or GILD? Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.68$4.09B$7.5538.53Gilead Sciences$28.74B4.62$480M$4.7522.43 Is AMGN or GILD more profitable? Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Amgen12.24% 176.32% 11.71% Gilead Sciences 1.67%31.63%10.38% Do insiders and institutionals hold more shares of AMGN or GILD? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, AMGN or GILD? Amgen has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Does the media prefer AMGN or GILD? In the previous week, Gilead Sciences had 21 more articles in the media than Amgen. MarketBeat recorded 67 mentions for Gilead Sciences and 46 mentions for Amgen. Amgen's average media sentiment score of 1.06 beat Gilead Sciences' score of 0.61 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 28 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 22 Very Positive mention(s) 5 Positive mention(s) 17 Neutral mention(s) 8 Negative mention(s) 2 Very Negative mention(s) Positive Do analysts rate AMGN or GILD? Amgen presently has a consensus price target of $310.57, indicating a potential upside of 6.75%. Gilead Sciences has a consensus price target of $110.55, indicating a potential upside of 3.76%. Given Amgen's higher probable upside, research analysts clearly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 10 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.43Gilead Sciences 0 Sell rating(s) 9 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.78 SummaryAmgen beats Gilead Sciences on 13 of the 22 factors compared between the two stocks. Get Amgen News Delivered to You Automatically Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMGN vs. The Competition Export to ExcelMetricAmgenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$156.41B$3.00B$5.57B$7.83BDividend Yield3.39%1.89%5.11%4.22%P/E Ratio38.5330.4222.4418.48Price / Sales4.68498.92394.09103.59Price / Cash9.98168.6838.1834.62Price / Book26.623.206.774.25Net Income$4.09B-$72.35M$3.22B$248.23M7 Day Performance3.96%1.46%1.49%0.89%1 Month Performance-5.21%8.79%4.00%3.53%1 Year Performance4.89%-22.36%16.21%5.08% Amgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMGNAmgen4.0689 of 5 stars$290.92+0.8%$310.57+6.8%+6.2%$156.41B$33.42B38.5325,200Positive NewsGILDGilead Sciences4.7021 of 5 stars$105.82+2.6%$109.43+3.4%+63.4%$131.51B$28.74B285.4617,000Earnings ReportDividend AnnouncementAnalyst RevisionVRTXVertex Pharmaceuticals3.9393 of 5 stars$492.87-0.2%$514.91+4.5%+29.7%$126.38B$11.02B-223.704,800Upcoming EarningsAnalyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.8331 of 5 stars$605.19+0.4%$945.32+56.2%-32.8%$66.19B$14.20B15.8211,900Earnings ReportDividend AnnouncementAnalyst ForecastALNYAlnylam Pharmaceuticals4.3115 of 5 stars$253.72+0.9%$315.58+24.4%+82.9%$33.05B$2.25B-117.092,000Analyst DowngradePositive NewsBIIBBiogen4.6894 of 5 stars$118.59-0.2%$203.07+71.2%-43.6%$17.33B$9.68B10.588,720Analyst DowngradeAnalyst RevisionUTHRUnited Therapeutics4.9052 of 5 stars$294.73+1.1%$390.17+32.4%+29.3%$13.24B$2.88B12.95980Earnings ReportAnalyst RevisionNews CoveragePositive NewsGap UpBMRNBioMarin Pharmaceutical4.9208 of 5 stars$62.55-1.2%$93.14+48.9%-21.1%$11.95B$2.85B28.463,080Positive NewsINCYIncyte4.7148 of 5 stars$58.97-0.3%$74.69+26.6%+20.4%$11.38B$4.24B217.892,320Earnings ReportAnalyst ForecastEXELExelixis4.0788 of 5 stars$38.13+1.9%$37.59-1.4%+66.9%$10.51B$2.17B21.551,220Short Interest ↑Analyst RevisionPositive NewsNBIXNeurocrine Biosciences4.8613 of 5 stars$105.21-1.4%$160.90+52.9%-21.7%$10.43B$2.36B32.031,200Upcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors BMRN Competitors INCY Competitors EXEL Competitors NBIX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMGN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMGN Stock Free AMGN Stock Alerts